T1	AdverseReaction 250 260	infections
T2	Severity 242 249	serious
T4	DrugClass 147 195	medications that work through inhibition of IL-1
T5	AdverseReaction 328 338	infections
T6	Severity 320 327	serious
T7	AdverseReaction 991 1001	infections
T8	Severity 983 990	serious
T9	AdverseReaction 1394 1404;1420 1450	Infections of the upper respiratory tract
T10	AdverseReaction 1394 1404;1420 1450	Infections of the upper respiratory tract
T11	Severity 1470 1477	serious
T12	AdverseReaction 1394 1404	Infections
T13	AdverseReaction 1535 1545	infections
T14	AdverseReaction 1606 1630	opportunistic infections
T15	AdverseReaction 1638 1651	aspergillosis
T16	AdverseReaction 1653 1686	atypical mycobacterial infections
T17	AdverseReaction 1620 1630;1688 1703	infections cytomegalovirus
T18	AdverseReaction 1705 1718	herpes zoster
T19	AdverseReaction 1973 1983	infections
T20	Severity 1965 1972	serious
T21	DrugClass 2035 2047	IL-1 blocker
T26	AdverseReaction 2488 2516	reactivation of tuberculosis
T27	AdverseReaction 2523 2547	opportunistic infections
T28	Factor 2480 2484	risk
T33	AdverseReaction 3717 3729	malignancies
T34	Factor 3709 3713	risk
T35	AdverseReaction 3768 3794	Hypersensitivity reactions
T36	AdverseReaction 3862 3884	anaphylactic reactions
T37	Negation 3859 3861	no
T38	AdverseReaction 4558 4595	interfere with normal immune response
T39	Factor 4554 4557	may
T40	AdverseReaction 5644 5647	MAS
T41	AdverseReaction 5820 5823	MAS
T42	Factor 975 979	risk
T43	AdverseReaction 1595 1602;1620 1630	unusual infections
T22	Factor 5846 5870	no definitive conclusion
E1	AdverseReaction:T1 Effect:E2 Hypothetical2:E4
E2	Severity:T2
E4	DrugClass:T4
E5	AdverseReaction:T5 Effect:E6
E6	Severity:T6
E7	AdverseReaction:T7 Effect:E8 Hypothetical:E43
E8	Severity:T8
E10	AdverseReaction:T9 Effect:E11
E9	AdverseReaction:T10
E11	Severity:T11
E12	AdverseReaction:T12
E13	AdverseReaction:T12 Effect:E11
E14	AdverseReaction:T13
E15	AdverseReaction:T14
E16	AdverseReaction:T15
E17	AdverseReaction:T16
E18	AdverseReaction:T17
E19	AdverseReaction:T18
E20	AdverseReaction:T19 Effect:E21 Hypothetical:E22
E21	Severity:T20
E22	DrugClass:T21
E27	AdverseReaction:T26 Hypothetical:E29
E28	AdverseReaction:T27 Hypothetical:E29
E29	Factor:T28
E34	AdverseReaction:T33 Hypothetical:E35
E35	Factor:T34
E36	AdverseReaction:T35
E37	AdverseReaction:T36 Negated:E38
E38	Negation:T37
E39	AdverseReaction:T38 Hypothetical:E40
E40	Factor:T39
E41	AdverseReaction:T40
E42	AdverseReaction:T41 Hypothetical:E23
E43	Factor:T42
E44	AdverseReaction:T43
E23	Factor:T22
A1	CUI E1 C3714514
A2	UMLS-Preferred-Name E1 Infection
A3	MEDDRA-PT E1 Infection
A4	MEDDRA-PT-ID E1 10021789
A5	CUI E5 C3714514
A6	UMLS-Preferred-Name E5 Infection
A7	MEDDRA-PT E5 Infection
A8	MEDDRA-PT-ID E5 10021789
A9	CUI E7 C3714514
A10	UMLS-Preferred-Name E7 Infection
A11	MEDDRA-PT E7 Infection
A12	MEDDRA-PT-ID E7 10021789
A13	CUI E10 C0041912
A14	UMLS-Preferred-Name E10 Upper Respiratory Infections
A15	MEDDRA-PT E10 Upper respiratory tract infection
A16	MEDDRA-PT-ID E10 10046306
A17	CUI E9 C0041912
A18	UMLS-Preferred-Name E9 Upper Respiratory Infections
A19	MEDDRA-PT E9 Upper respiratory tract infection
A20	MEDDRA-PT-ID E9 10046306
A21	CUI E12 C3714514
A22	UMLS-Preferred-Name E12 Infection
A23	MEDDRA-PT E12 Infection
A24	MEDDRA-PT-ID E12 10021789
A25	CUI E14 C3714514
A26	UMLS-Preferred-Name E14 Infection
A27	MEDDRA-PT E14 Infection
A28	MEDDRA-PT-ID E14 10021789
A29	CUI E15 C0029118
A30	UMLS-Preferred-Name E15 Opportunistic Infections
A31	MEDDRA-PT E15 Opportunistic infection
A32	MEDDRA-PT-ID E15 10030901
A33	CUI E16 C0004030
A34	UMLS-Preferred-Name E16 Aspergillosis
A35	MEDDRA-PT E16 Aspergillus infection
A36	MEDDRA-PT-ID E16 10074171
A37	LLT E16 Aspergillosis
A38	LLT-ID E16 10003488
A39	CUI E17 C0026919
A40	UMLS-Preferred-Name E17 Mycobacterium Infections, Nontuberculous
A41	MEDDRA-PT E17 Atypical mycobacterial infection
A42	MEDDRA-PT-ID E17 10061663
A43	CUI E18 C0010823
A44	UMLS-Preferred-Name E18 Cytomegalovirus Infections
A45	MEDDRA-PT E18 Cytomegalovirus infection
A46	MEDDRA-PT-ID E18 10011831
A47	CUI E19 C0019360
A48	UMLS-Preferred-Name E19 Herpes zoster disease
A49	MEDDRA-PT E19 Herpes zoster
A50	MEDDRA-PT-ID E19 10019974
A51	CUI E20 C3714514
A52	UMLS-Preferred-Name E20 Infection
A53	MEDDRA-PT E20 Infection
A54	MEDDRA-PT-ID E20 10021789
A55	CUI E27 C0275965
A56	UMLS-Preferred-Name E27 Reactivation tuberculosis
A57	MEDDRA-PT E27 Tuberculosis
A58	MEDDRA-PT-ID E27 10044755
A59	LLT E27 Tuberculosis reactivated
A60	LLT-ID E27 10045025
A61	CUI E28 C0029118
A62	UMLS-Preferred-Name E28 Opportunistic Infections
A63	MEDDRA-PT E28 Opportunistic infection
A64	MEDDRA-PT-ID E28 10030901
A65	CUI E34 C0006826
A66	UMLS-Preferred-Name E34 Malignant Neoplasms
A67	MEDDRA-PT E34 Neoplasm malignant
A68	MEDDRA-PT-ID E34 10028997
A69	CUI E36 C0020517
A70	UMLS-Preferred-Name E36 Hypersensitivity
A71	MEDDRA-PT E36 Hypersensitivity
A72	MEDDRA-PT-ID E36 10020751
A73	LLT E36 Hypersensitivity reaction
A74	LLT-ID E36 10020756
A75	CUI E37 C0002792
A76	UMLS-Preferred-Name E37 anaphylaxis
A77	MEDDRA-PT E37 Anaphylactic reaction
A78	MEDDRA-PT-ID E37 10002198
A79	CUI E39 C0863087
A80	UMLS-Preferred-Name E39 Decreased immune responsiveness
A81	MEDDRA-PT E39 Decreased immune responsiveness
A82	MEDDRA-PT-ID E39 10011968
A83	CUI E41 C1096155
A84	UMLS-Preferred-Name E41 Macrophage Activation Syndrome
A85	MEDDRA-PT E41 Histiocytosis haematophagic
A86	MEDDRA-PT-ID E41 10048595
A87	LLT E41 Macrophage activation syndrome
A88	LLT-ID E41 10053867
A89	CUI E42 C1096155
A90	UMLS-Preferred-Name E42 Macrophage Activation Syndrome
A91	MEDDRA-PT E42 Histiocytosis haematophagic
A92	MEDDRA-PT-ID E42 10048595
A93	LLT E42 Macrophage activation syndrome
A94	LLT-ID E42 10053867
A95	CUI E44 C3714514
A96	UMLS-Preferred-Name E44 Infection
A97	MEDDRA-PT E44 Infection
A98	MEDDRA-PT-ID E44 10021789
